India IDExchange
Sign up
Limited time. Limited Seats.|Foresight ₹85,000 ₹60,000 + 18% GST|12 months of accessGet Foresight

India ID Exchange · Board Seats

NRC Chair Roles in Healthcare and Pharma Industry in India

The national NRC chair hub for healthcare and pharma boards—live roles, critical-talent succession, term evidence and fee bands.

India's healthcare leadership market spans pharma, hospitals, diagnostics and emerging medtech. The committee must test technical authority and culture in the context of the actual regulated activity.

Seats on this page
0
Open now
0
Forecast to open
41
Boards read daily
3,790
Deploy our search agentJump to open seats

Company identity, per-firm fees, deadline and the full brief remain Foresight-only.

01

The seats

What is live now, what the filings suggest is approaching, and what changed on tracked boards.

Open NRC chair seats—healthcare and pharma across India

Every live location is eligible and counted in the distribution. Sector prose and regulatory rows use healthcare evidence, not the reference page's RBI layer.

No nrc chair seat in India is open on the Exchange today.

Seats of this exact shape surface irregularly. The Exchange reads 3,790 boards every day and most appointments become visible weeks before they are advertised anywhere — Foresight members are matched to them as they form. The closely related seats below are open right now.

Get matched as these open

Other committees in India (8)

Open seats on the same sector’s boards in India, on committees other than the nrc chair.

What is hidden on the 8 seats above

  • · The company behind each mandate, where it has authorised disclosure
  • · Sitting fees, committee fees and annual retainer — always members-only
  • · The application deadline and the full mandate brief
  • · Direct application, without waiting for a seat to open to free members

NRC Chair Roles in Healthcare and Pharma Industry in India is a narrow, high-competition shape. Foresight members apply the day a seat is posted, up to ten a day; free members wait for the deadline window and a cap of one application a week. On a shortlist of five, that timing is the contest.

Unlock with Foresight

Seats forecast to reach a term boundary

The latest filings record 285 sitting chairs in this cohort. The counts below are term-boundary signals, not announced vacancies; reappointments and early exits can move the date.

31

First term completing

Four to five years served; the board can renew or reopen the skills question.

7

Second term completing

Nine to ten years served; a further consecutive term is unavailable.

3

Past ten years

A succession signal that requires examination, not a claim about any named director.

Board movements in the latest filing period

Exchange filings for Jun 2026 recorded 62 appointments and 54 departures in this page’s measured market. These are filed movements, not inferred vacancies.

MovementBoardDirectorFiled category
AppointedCipla LimitedAchin GuptaExecutive Director
DepartedCipla LimitedUmang VohraExecutive Director
AppointedSun Pharmaceutical Industries LimitedSatyavati BereraNon-Executive - Independent Director
AppointedSun Pharmaceutical Industries LimitedAndreas BuschNon-Executive - Independent Director
AppointedAbbott India LimitedNeeraj JainNon-Executive - Independent Director
AppointedAbbott India LimitedJames WennerNon-Executive - Non Independent Director
AppointedGlaxoSmithkline Pharmaceticuals LimitedRonojit BiswasExecutive Director
AppointedSANOFI INDIA LIMITEDSiraj ChaudhryNon-Executive - Independent Director
AppointedSANOFI INDIA LIMITEDRajani KesariNon-Executive - Independent Director
AppointedNEULAND LABORATORIES LIMITEDMauricio FutranNon-Executive - Non Independent Director
Monitor movements with Foresight
02

The market

The incumbent pool, term pattern, concentration, committee resilience, representation and disclosed pay.

Who holds this seat today

The census is the direct national healthcare NRC cohort, with every statistic queried from the sector's own filing rows.

285

Sitting chairs

1

Median listed boards

23.7%

Holding 3+ boards

7 : 1

Incumbents / boundary

Tenure profile

Under 2 years81 · 28.4%
2 to 5 years155 · 54.4%
5 to 8 years34 · 11.9%
8 to 10 years12 · 4.2%
Over 10 years3 · 1.1%

33

Appointments in 12 months

Filed arrivals only; cessation data is not populated well enough to publish reasons for departure.

11.6%

Observed arrival rate

This is not converted into an implied tenure; that inference conflicts with the measured histogram.

52.4%

Newcomers on one board

Capacity, not an already-large portfolio, is visible in the newly appointed cohort.

Committee floor and representation

56.3%

At the three-member floor

2

Below three members in the filing

31.2%

Women among recorded chairs, versus 32.3% of members

What the seat pays

Public bands answer the market question without exposing the company-specific figure. The rows below are computed from 234 annual-report records; each denominator is shown.

BenchmarkP25MedianP75P90
Board meeting n=50₹25,000₹50,000₹1 lakh₹1 lakh
Committee meeting n=43₹25,000₹50,000₹1 lakh₹1 lakh
Annual per ID n=58₹1.5 lakh₹4 lakh₹12.8 lakh₹30 lakh
Highest-paid ID n=58₹2 lakh₹5.2 lakh₹18 lakh₹30 lakh

Ranges across companies, not offers. Per-company fees remain gated on each seat’s own detail page.

Open the ID salary benchmark
03

The seat itself

The work behind the title, the sector-specific judgement it requires, and the evidence a nomination committee will test.

What the role actually owns

Architecture

Board composition

Translate strategy into a skills matrix, identify the capability the board lacks and run a defensible recommendation process.

Succession

CEO and leadership succession

Maintain named emergency and planned-successor options, with evidence of readiness rather than a slide of possible names.

Pay

Remuneration design

Connect fixed pay, variable pay, long-term incentives and consequence management to risk-adjusted performance.

Governance

Evaluation and independence

Own the criteria, conflicts review and recommendation trail that make independence substantive rather than ceremonial.

Why healthcare succession carries patient and product consequence

The NRC is choosing leaders for regulated science, clinical operations and patient-facing systems. A weak appointment can surface later as quality failure, trial delay, data-integrity concern or a culture in which bad news travels too slowly.

Authority

Technical authority matters

Quality, medical, regulatory and pharmacovigilance leaders need enough independence and stature to stop a commercial timetable.

Incentives

Pipelines distort incentives

Milestones can reward enrolment, approvals or launches before durable safety, quality and access outcomes are visible.

Scope

Succession is cross-border

Key roles often span Indian operations, global regulators, research partners and specialist talent markets.

Do you qualify for this seat?

A healthcare NRC tests whether the candidate can govern expert leadership without substituting prestige for evidence or commercial urgency for fitness.

  1. 01 · Culture

    Quality-culture judgement

    Show how you protected an escalation channel or strengthened authority for a control function.

  2. 02 · Sector

    Regulated-talent exposure

    Understand the accountability of quality, medical, regulatory and clinical leaders.

  3. 03 · Evidence

    Science-to-board translation

    Challenge claims and milestones without pretending to be the principal investigator.

  4. 04 · Pay

    Incentive design

    Connect reward to quality, safety, compliance and sustainable access—not only launch or sales targets.

  5. 05 · Pipeline

    Cross-border succession

    Bring a talent map that accounts for regulator credibility, jurisdiction and scarce specialisms.

  6. 06 · Threshold

    Independence and time

    Disclose industry advisory work and reserve capacity for inspections, recalls or sensitive appointments.

04

Doing the job

The dated obligations, the first hundred days, and a practical checklist for the work behind the appointment.

The regulatory year

Healthcare pages replace the financial-services RBI row with the CDSCO, drugs-and-cosmetics, clinical and quality layer that shapes accountable appointments.

First board meeting of the year

Companies Act s.149(7)

Record each independent director's declaration and test conflicts against the current group structure, not last year's chart.

At least once each financial year

Applicable LODR committee regulation

Meet the statutory minimum, but schedule decisions when the evidence is available; an annual formality is not active oversight.

Annual independent-director meeting

LODR Reg. 25(3)

Use the session without management to surface information gaps and agree what must return to the full board.

Before the annual evaluation

LODR Schedule II

Set evaluation criteria before scoring begins and preserve the evidence behind difficult conclusions.

By 30 September

MCA DIR-3 KYC

Confirm every DIN remains active. Administrative lapse can disable a director at the point a committee most needs continuity.

Before critical quality, medical and regulatory appointments

Drugs and Cosmetics Act / CDSCO framework

Test technical qualification, independence, authority and regulator credibility before treating a candidate as appointment-ready.

Across product and trial milestones

NDCTR, pharmacovigilance and quality-system obligations

Align leadership scorecards with safety, data integrity, quality and timely escalation as well as commercial delivery.

Provision summaries are orientation, not legal advice. Verify the current Act, Listing Regulations and sector direction before relying on an item.

Your first hundred days

The incoming chair should make critical-role authority and succession visible before a quality or clinical event tests it.

  1. Days 1–15

    Map critical accountable roles

    Identify quality, medical, regulatory, clinical and patient-safety positions whose vacancy changes risk immediately.

  2. Days 15–30

    Test speak-up authority

    Ask who can stop release, enrolment or promotion and how the board would learn that they tried.

  3. Days 30–45

    Read reward against quality

    Trace variable-pay measures for signals that volume or timetable can outrank safety and data integrity.

  4. Days 45–60

    Review succession credibility

    Require ready-now and developable options for each regulated critical role, including cross-border constraints.

  5. Days 60–80

    Challenge expert evaluation

    Ensure board assessment tests the decisions specialist directors improve rather than their credentials alone.

  6. Days 80–100

    Put culture into the scorecard

    Agree measurable evidence of escalation, investigation quality and remediation closure for senior leaders.

Get the NRC Chair Readiness Checklist

Two pages, free. The appointment tests that decide whether you may chair at all, the four documents to demand before your first meeting, the RBI compensation and fit-and-proper layer that applies to banks, NBFCs and insurers, and the annual cycle most committees miss. Written to be worked through.

No cost. We hold your details only to send board-seat information you asked for, and you can withdraw at any time.

Questions directors actually ask

Must a healthcare NRC chair be a doctor?

No. Clinical or scientific fluency helps, but the chair's core job is nomination, succession, reward and evaluation across expert functions.

What replaces the RBI layer on this page?

Healthcare appointments are shaped by CDSCO, drugs-and-cosmetics, clinical-trial, pharmacovigilance and quality-system responsibilities.

How should quality affect executive pay?

Scorecards should include safety, data integrity, inspection, deviation and remediation evidence so commercial delivery cannot overwhelm control outcomes.

Which roles are most succession-sensitive?

Quality, medical, regulatory, pharmacovigilance and clinical leadership can carry statutory or licence-critical authority and scarce expertise.

Are term forecasts announced vacancies?

No. They are aggregate appointment-date signals and are never published as a named-company hiring assertion.

Can a pharma NRC chair move to a hospital board?

The nomination craft transfers, but patient operations, medical governance, workforce scale and revenue context require fresh sector diligence before claiming fit.

India ID Exchange Foresight

Deploy our search agent before the shortlist is already written

We read 3,790 boards daily, find the roles that fit your committee, sector and geography, and put the brief, fees and deadline in front of you early.

Start Foresight

Related board-seat resources

Before you apply

What this committee is accountable for, what the seat pays, and how much capacity it will take.